GlassScriptPhysician profile
Emily Jeffries
NPI 1093704934
$1,696.27
in general payments reported to CMS, 2019-2025
28 companies · $40.39 in 2025
The $40.39 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $389 · 2023: $105 · 2024: $190 · 2025: $40.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $335.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $275.96 | 2019-2024 | Breztri, Farxiga |
| Lilly USA, LLC | $218.32 | 2019-2023 | Mounjaro |
| Kowa Pharmaceuticals America, INC. | $171.41 | 2019-2020 | |
| Amarin Pharma, INC. | $107.98 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.06 | 2019-2020 | |
| Exact Sciences Corporation | $82.76 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $72.38 | 2019-2024 | |
| Novo Nordisk INC | $65.62 | 2019-2020 | |
| Pfizer INC. | $65.21 | 2019-2025 | |
| Abbott Laboratories | $60.92 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $57.81 | 2019-2024 | Arexvy |
| Genentech USA, INC. | $55.91 | 2019-2020 | |
| Allergan, INC. | $53.98 | 2020 | |
| Merck Sharp & Dohme LLC | $53.07 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.76 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $29.14 | 2019 | |
| Arbor Pharmaceuticals, INC. | $27.22 | 2019-2020 | |
| Valeritas, INC. | $18.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.95 | 2023 | |
| Amgen INC. | $15.00 | 2019 | |
| Eisai INC. | $14.37 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.29 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.19 | 2024 | Nuzyra |
| Endo Pharmaceuticals INC. | $14.14 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.85 | 2020 | |
| Daiichi Sankyo INC. | $13.64 | 2020 | |
| Shire North American Group INC | $13.05 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Jeffries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.